Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding

Journal of Molecular Biology

Volumn 315, Issue 4, 2002, Pages 573-586

  Trang, Phong ^a   Hsu, Amy ^a   Zhou, Tianhong ^a   Lee, Jarone ^a   Kilani, Ahmed F ^a   Nepomuceno, Edward ^a   Liu, Fenyong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral; Gene targeting; Human cytomegalovirus; Ribozyme; RNase P

Indexed keywords

ENZYME VARIANT; MESSENGER RNA; NUCLEOTIDE; REGULATOR PROTEIN; RIBONUCLEASE P; RIBOZYME;

ARTICLE; BINDING AFFINITY; CELL CULTURE; CODING; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME ENGINEERING; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO SELECTION; IN VITRO STUDY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RNA CLEAVAGE; RNA SEQUENCE; TRANSCRIPTION REGULATION; VIROGENESIS; WILD TYPE;

CYTOMEGALOVIRUS; ESCHERICHIA COLI; HUMAN HERPESVIRUS 5;

EID: 0036304083     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.5291     Document Type: Article

References (80)

1. Cytomegalovirus
2. Cytomegaloviruses and their replication
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators
4. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
5. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992
6. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993
7. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
8. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
9. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs
10. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015
11. Cytomegalovirus retinitis and response to therapy with ganciclovir
12. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS
13. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
14. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis
15. The Cys607 → Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients
16. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS
17. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance
18. Anti-sense catalytic RNAs as therapeutic agents
19. Antiviral and anticancer ribozymes
20. Ribozymes, genomics and therapeutics
21. Conservation of a hairpin ribozyme sequence in HIV-1 is required for efficient viral replication
22. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus
23. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1
24. Ribozymes as potential anti-HIV-1 therapeutic agents
25. Monitoring retroviral RNA dimerization in vivo via hammerhead ribozyme cleavage
26. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors
27. Group II introns designed to insert into therapeutically relevant DNA target sites in human cells
28. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo
29. A controlled. Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
30. Ribonuclease P
31. Ribonuclease P: Unity and diversity in a tRNA processing ribozyme
32. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
33. Model substrates for an RNA enzyme
34. External guide sequences for an RNA enzyme
35. Rational design of self-cleaving pre-tRNA-Rribonuclease P RNA conjugates
36. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli
37. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment
38. Differential effects of the protein cofactor on the interactions between a RNase P ribozyme and its target mRNA substrate
39. Nuclease footprint analyses of the interactions between RNase P ribozyme and a model mRNA substrate
40. UV crosslink mapping of the substrate binding site of RNase P ribozyme to a target mRNA sequence
41. RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture
42. Effective inhibition of human cyto-megalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli
43. A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1
44. Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region
45. Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1
46. RNA: The shape of things to come
47. Directed molecular evolution
48. In vitro selection of functional RNA sequences
49. Human cyto-megalovirus with IE-2 (UL122) deleted fails to express early lytic genes
50. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant
51. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
52. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
53. Lethal and temperature-sensitive mutations and their suppressors identify an essential structural element in U2 small nuclear RNA
54. Analysis of the structure of Tetrahymena nuclear RNAs in vivo: Telomerase RNA, the self-splicing rRNA intron, and U2 snRNA
55. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169
56. The protein cofactor allows the sequence of an RNase P ribozyme to diversify by maintaining the catalytically active structure of the enzyme
57. Multiple magnesium ions in the ribonuclease P reaction mechanism
58. Influence of metal ions on the ribonuclease P reaction distinguishing substrate binding from catalysis
59. Targeted cleavage of mRNA by human RNase P
60. Upstream regulatory elements are necessary and sufficient for transcription of a U6 RNA gene by RNA polymerase III
61. Inhibition of viral gene expression by human ribonuclease P
62. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization
63. Improved retroviral vectors for gene transfer and expression
64. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: Induction of interferon-responsive RNAs
65. Reconstitution of RNase P activity using inactive subuits from E. coli and HeLa cells
66. A subunit of human nuclear RNase P has ATPase activity
67. Human ribonuclease P
68. Escherichia coli proteins, including ribosomal protein S12, facilitate in vitro splicing of phage T4 introns by acting as RNA chaperones
69. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1
70. Protein enhancement of hammerhead ribozyme catalysis
71. Comparative photocross-linking analysis of the tertiary structures of Escherichia coli and Bacillus subtilis RNase P RNAs
72. Derivation of the three-dimensional architecture of bacterial ribonuclease P RNAs from comparative sequence analysis
73. Epstein-Barr virus and its replication
74. Herpes simplex viruses and their replication
75. Toward a comprehensive phylogeny for mammalian and avian herpesviruses
76. Kinetics of intermolecular cleavage by hammerhead ribozymes
77. Direct measurement of oligonucleotide substrate binding to wild-type and mutant ribozymes from Tetrahymena
78. The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate
79. Evolutionary variation in bacterial RNase P RNAs
80. Further perspective on the catalytic core and secondary structure of ribonuclease P RNA